Evidence map›Paper›PMID 29371766›Full record

ArticleIndian journal of clinical biochemistry : IJCB2018

Possible Role of microRNA-122 in Modulating Multidrug Resistance of Hepatocellular Carcinoma.

Shaymaa M M Yahya, Shadia A Fathy, Zakaria A El-Khayat, Safinaz E El-Toukhy, Ahmed R Hamed, Marwa G A Hegazy, Heba K Nabih

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Indian journal of clinical biochemistry : IJCB, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 39 citations in OpenAlex.

  1. Role of miRNA‑122 in cancer (Review).International journal of oncology · 2024
    Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Shaymaa M M Yahya1Hormones Department, National Research Centre, Dokki, Giza, 12622 Egypt.
Shadia A Fathy2Biochemistry Department, Ain Shams University, Cairo, Egypt.
Zakaria A El-Khayat3Medical Biochemistry Department, National Research Centre, Cairo, Egypt.
Safinaz E El-Toukhy3Medical Biochemistry Department, National Research Centre, Cairo, Egypt.
Ahmed R Hamed4Pharmaceutical Research Group, Center of Excellence for Advanced Sciences and Phytochemistry Department National Research Centre, Dokki, Giza, Egypt.
Marwa G A Hegazy2Biochemistry Department, Ain Shams University, Cairo, Egypt.
Heba K Nabih3Medical Biochemistry Department, National Research Centre, Cairo, Egypt.
National Research Centre · EGAin Shams University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a hypervascular primary liver cancer characterized by rapid progression, besides, resistance to traditional chemotherapeutic agents. It has been shown that microRNAs play critical roles in regulation of tumor cell sensitivity to drugs through modulating the expression of genes involved in drug transport. The present study investigated whether restoration of miR-122 in HCC cells could alter the cell cycle distribution and the expression of multidrug resistance (MDR)-related genes (ABCB1, ABCC1, ABCG2 and ABCF2). After overexpression of miR-122 in HepG2 cells treated or untreated with doxorubicin doses, total RNAs and protein extracts were isolated for application of QRT-PCR and western blotting techniques. Moreover, cell cycle distribution was monitored by flow cytometry. Our results revealed that, the over expression of miR-122 in HepG2 cells treated or untreated with doxorubicin could modulate the sensitivity of cells to chemotherapeutic drug through downregulation of MDR-related genes, ABCB1 and ABCF2. Interpretation of cell cycle distribution revealed that, the anti-proliferative effect of miR-122 is associated with the accumulation of cells in G

Indexed as

ABCsCell cycleHepatocellular carcinomaMDRmiRNA-122

Identifiers

PMID29371766
PMCPMC5766467
OpenAlexW2606288136

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.